PFIZER LAUNCHES ONLINE PIPELINE WATCH

Pfizer announced Dec. 20 it is launching an online site where the progress of compounds in its research and development pipeline will be made available to investors, plus the scientific and medical communities, and regularly updated.

The new site provides details of Pfizer's pipeline and research in cancer, heart disease, diabetes, neurological and infectious diseases and other disease areas. The site includes clinical programs from Phase I compounds to late-stage medicines under regulatory review, plus recently-approved products.

"Today's posting will provide investors as well as the scientific and medical communities with more detail on our pipeline than ever before, as well as the ability to see updates on our progress," said John LaMattina, president of Pfizer Global Research and Development.

The launch follows the company's commitment, made to analysts and investors at its Nov. 30 R&D briefing, to make available pipeline details before the end of this year. At that briefing, the company described 30 research programs, with more than half highlighted for the first time. Pfizer's pipeline has nearly 250 preclinical and clinical programs, including 169 new molecular entities.